株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

塞栓療法の世界市場 - 2024年までの予測:塞栓剤 (マイクロスフィア、塞栓コイル、液体塞栓剤、塞栓プラグシステム、離脱型バルーン)、補助装置 (マイクロカテーテル、ガイドワイヤー)

Embolotherapy Market by Product (Embolic Agents (Microspheres, Detachable Coils, Pushable Coils), Guidewires), Disease (Oncology, Aneurysm, Peripheral Vascular), Procedure, End User (Hospitals, Clinics, ASC, Academia) - Global Forecast to 2024

発行 MarketsandMarkets 商品コード 906162
出版日 ページ情報 英文 220 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.15円で換算しております。
Back to Top
塞栓療法の世界市場 - 2024年までの予測:塞栓剤 (マイクロスフィア、塞栓コイル、液体塞栓剤、塞栓プラグシステム、離脱型バルーン)、補助装置 (マイクロカテーテル、ガイドワイヤー) Embolotherapy Market by Product (Embolic Agents (Microspheres, Detachable Coils, Pushable Coils), Guidewires), Disease (Oncology, Aneurysm, Peripheral Vascular), Procedure, End User (Hospitals, Clinics, ASC, Academia) - Global Forecast to 2024
出版日: 2019年08月07日 ページ情報: 英文 220 Pages
概要

塞栓療法市場は、2019年の33億米ドルから、2024年までに49億米ドルまで拡大すると見られています。市場は、2019年~2024年のCAGR (複合年間成長率) で、8.1%の成長が予測されています。

当レポートでは、世界の塞栓療法市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 塞栓療法:市場概要
  • 塞栓療法市場:製品別
  • 塞栓療法市場:処置別、地域別
  • 塞栓療法市場:適応疾患別
  • アジア太平洋地域の塞栓療法市場:エンドユーザー別、国別
  • 塞栓療法市場の地域別スナップショット

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 塞栓療法の世界市場:製品別

  • イントロダクション
  • 塞栓剤
    • マイクロスフィア
    • 塞栓コイル
    • 液体塞栓剤
    • 塞栓プラグシステム
    • 離脱型バルーン
  • 補助装置
    • マイクロカテーテル
    • ガイドワイヤー

第7章 塞栓療法の世界市場:適応疾患別

  • イントロダクション
  • がん
    • 肝臓がん
    • 腎臓がん
    • その他のがん
  • 末梢血管疾患
  • 神経疾患
  • 動静脈奇形
  • 泌尿器・腎疾患
  • 胃腸障害

第8章 塞栓療法の世界市場:処置別

  • イントロダクション
  • 経カテーテル動脈塞栓療法 (TAE)
  • 経カテーテル動脈放射線塞栓療法 (TARE) / 選択的内部放射線療法 (SIRT)
  • 経カテーテル動脈化学塞栓療法 (TACE)

第9章 塞栓療法の世界市場:エンドユーザー別

  • イントロダクション
  • 病院・クリニック
  • 外来外科センター
  • その他

第10章 塞栓療法の世界市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • イントロダクション
  • 市場シェア分析
  • 競合状況・動向
  • 競合リーダーシップマッピング
  • ベンダー選定基準
  • ベンダー分析

第12章 企業プロファイル

  • ABBOTT LABORATORIES
  • ACANDIS GMBH
  • BALT EXTRUSION
  • BOSTON SCIENTIFIC CORPORATION
  • BTG PLC
  • COOK MEDICAL
  • JOHNSON & JOHNSON
  • カネカ
  • MEDTRONIC PLC
  • MERIL LIFE SCIENCES PVT., LTD.
  • MERIT MEDICAL SYSTEMS
  • PENUMBRA, INC.
  • SIRTEX MEDICAL LIMITED
  • STRYKER CORPORATION
  • テルモ

第13章 付録

図表

LIST OF TABLES

  • TABLE 1: PRIMARY LIVER CANCER INCIDENCE AMONG MEN AND WOMEN (2005 VS 2030)
  • TABLE 2: GERIATRIC POPULATION, BY REGION, 2015 VS 2030
  • TABLE 3: MEDICAL REIMBURSEMENT CPT CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019)
  • TABLE 4: MEDICAL REIMBURSEMENT MS-DRG CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019)
  • TABLE 5: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 6: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 7: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 8: EMBOLIC AGENTS, BY TYPE
  • TABLE 9: EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 10: EMBOLIC COILS OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 11: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 12: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 13: EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 14: EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 15: EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 16: EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 17: EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 18: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 19: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 20: EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 21: EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 22: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024
  • TABLE 23: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, 2017-2024
  • TABLE 24: EMBOLOTHERAPY MARKET FOR CANCER, BY REGION, 2017-2024
  • TABLE 25: EMBOLOTHERAPY MARKET FOR LIVER CANCER, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 26: EMBOLOTHERAPY MARKET FOR KIDNEY CANCER, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 27: EMBOLOTHERAPY MARKET FOR OTHER CANCERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 28: EMBOLOTHERAPY MARKET FOR PERIPHERAL VASCULAR DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 29: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, 2017-2024
  • TABLE 30: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 31: EMBOLOTHERAPY MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 32: EMBOLOTHERAPY MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 33: EMBOLOTHERAPY MARKET FOR UROLOGICAL & NEPHROLOGICAL DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 34: EMBOLOTHERAPY MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 35: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 36: TRANSCATHETER ARTERIAL EMBOLIZATION MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 37: TRANSCATHETER ARTERIAL RADIOEMBOLIZATION MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 38: TRANSARTERIAL CHEMOEMBOLIZATION MARKET, BY REGION, 2017-2024
  • TABLE 39: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 40: EMBOLOTHERAPY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 41: EMBOLOTHERAPY MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 42: EMBOLOTHERAPY MARKET FOR OTHER END USERS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 43: EMBOLOTHERAPY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 44: NORTH AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 45: NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 46: NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 47: NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 48: NORTH AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 49: NORTH AMERICA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 50: NORTH AMERICA: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 51: NORTH AMERICA: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 52: NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 53: NORTH AMERICA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 54: MEDICARE REIMBURSEMENT FOR TRANSCATHETER EMBOLIZATION OR OCCLUSION SERVICES: 2019
  • TABLE 55: US: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 56: US: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 57: US: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 58: US: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 59: US: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 60: US: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 61: US: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 62: CANADA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 63: CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 64: CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 65: CANADA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 66: CANADA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 67: CANADA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 68: CANADA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 69: EUROPE: EMBOLOTHERAPY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 70: EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 71: EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 72: EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 73: EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 74: EUROPE: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 75: EUROPE: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 76: EUROPE: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 77: EUROPE: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 78: EUROPE: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 79: GERMANY: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 80: GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 81: GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 82: GERMANY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 83: GERMANY: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 84: GERMANY: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 85: GERMANY: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 86: UK: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 87: UK: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 88: UK: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 89: UK: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 90: UK: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 91: UK: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 92: UK: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 93: FRANCE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 94: FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 95: FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 96: FRANCE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 97: FRANCE: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 98: FRANCE: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 99: FRANCE: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 100: ROE: HEALTH EXPENDITURE, BY COUNTRY (2017)
  • TABLE 101: AGING POPULATION (% SHARE OF THE TOTAL POPULATION), BY COUNTRY, 2015 VS. 2030 (IN MILLION)
  • TABLE 102: CANCER INCIDENCE, BY COUNTRY, 2018
  • TABLE 103: ROE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 104: ROE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 105: ROE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 106: ROE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 107: ROE: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 108: ROE: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 109: ROE: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 110: ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 111: ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 112: ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 113: ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 114: ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 115: ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 116: ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 117: ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 118: ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 119: ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 120: JAPAN: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 121: JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 122: JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 123: JAPAN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 124: JAPAN: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 125: JAPAN: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 126: JAPAN: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 127: CHINA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 128: CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 129: CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 130: CHINA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 131: CHINA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 132: CHINA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 133: CHINA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 134: INDIA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 135: INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 136: INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 137: INDIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 138: INDIA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 139: INDIA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 140: INDIA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 141: ROAPAC: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 142: ROAPAC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 143: ROAPAC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 144: ROAPAC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 145: ROAPAC: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 146: ROAPAC: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 147: ROAPAC: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 148: LATIN AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 149: LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 150: LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 151: LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 152: LATIN AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 153: LATIN AMERICA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 154: LATIN AMERICA: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 155: LATIN AMERICA: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 156: LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 157: LATIN AMERICA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 158: BRAZIL: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 159: BRAZIL: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 160: BRAZIL: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 161: BRAZIL: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 162: BRAZIL: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 163: BRAZIL: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 164: BRAZIL: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 165: ROLA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 166: ROLA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 167: ROLA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 168: ROLA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 169: ROLA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 170: ROLA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 171: ROLA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 172: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 173: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 174: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 175: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 176: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 177: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 178: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 179: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION)
  • TABLE 180: MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 181: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 182: COLLABORATIONS
  • TABLE 183: EXPANSIONS
  • TABLE 184: ACQUISITIONS

LIST OF FIGURES

  • FIGURE 1: EMBOLOTHERAPY MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARIES: EMBOLOTHERAPY MARKET
  • FIGURE 4: RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 5: BOTTOM-UP APPROACH MARKET SIZE ESTIMATION: EMBOLOTHERAPY MARKET
  • FIGURE 6: TOP-DOWN APPROACH MARKET SIZE ESTIMATION: EMBOLOTHERAPY MARKET
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2024 (USD MILLION)
  • FIGURE 9: EMBOLOTHERAPY MARKET SHARE, BY DISEASE INDICATION, 2019 VS. 2024
  • FIGURE 10: EMBOLOTHERAPY MARKET SHARE, BY PROCEDURE, 2019-2024 (USD MILLION)
  • FIGURE 11: EMBOLOTHERAPY MARKET, BY END USER, 2019-2024 (USD MILLION)
  • FIGURE 12: EMBOLOTHERAPY MARKET, BY REGION: GEOGRAPHICAL SNAPSHOT
  • FIGURE 13: RISING INCIDENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE EMBOLOTHERAPY MARKET ACROSS THE GLOBE
  • FIGURE 14: MICROSPHERES SEGMENT WILL WITNESS HIGH GROWTH IN THE MARKET
  • FIGURE 15: TRANSCATHETER ARTERIAL EMBOLIZATION SEGMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2019
  • FIGURE 16: CANCER SEGMENT TO DOMINATE THE EMBOLOTHERAPY MARKET DURING THE FORECAST PERIOD
  • FIGURE 17: AMBULATORY SURGERY CENTERS SEGMENT WILL REGISTER THE HIGHEST CAGR IN ASIA PACIFIC
  • FIGURE 18: CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 19: EMBOLOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 20: NORTH AMERICA: EMBOLOTHERAPY MARKET SNAPSHOT
  • FIGURE 21: EUROPE: EMBOLOTHERAPY MARKET SNAPSHOT
  • FIGURE 22: ASIA PACIFIC: EMBOLOTHERAPY MARKET SNAPSHOT
  • FIGURE 23: KEY DEVELOPMENTS IN THE EMBOLOTHERAPY MARKET FROM 2015 TO 2019
  • FIGURE 24: BTG PLC ACCOUNTED FOR THE LARGEST SHARE OF THE MICROSPHERES MARKET IN 2018
  • FIGURE 25: STRYKER HELD THE LEADING POSITION OF THE EMBOLIZATION COILS MARKET IN 2018
  • FIGURE 26: EMBOLOTHERAPY MARKET:GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2018
  • FIGURE 27: ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 28: BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • FIGURE 29: BTG PLC: COMPANY SNAPSHOT
  • FIGURE 30: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 31: KANEKA CORPORATION: COMPANY SNAPSHOT
  • FIGURE 32: MEDTRONIC PLC: COMPANY SNAPSHOT
  • FIGURE 33: MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT
  • FIGURE 34: PENUMBRA, INC.: COMPANY SNAPSHOT
  • FIGURE 35: SIRTEX MEDICAL LIMITED: COMPANY SNAPSHOT
  • FIGURE 36: STRYKER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 37: TERUMO CORPORATION: COMPANY SNAPSHOT
目次
Product Code: MD 7279

"The embolotherapy market is projected to grow at a CAGR of 8.1% during the forecast period"

The embolotherapy market is projected to reach USD 4.9 billion by 2024 from USD 3.3 billion in 2019, at a CAGR of 8.1% from 2019 to 2024. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Moreover, increasing demand for minimally invasive procedures, favorable reimbursement scenario, and new product launches in the market are further supporting the growth of the market over the forecast period. However, stringent regulatory frameworks for product commercialization and the strong market positioning of alternative treatments are expected to limit the optimal adoption of embolotherapy devices during the forecast period.

"The cancer segment, by disease indication, accounted for the largest share of the embolotherapy market in 2018"

In terms of disease indication, embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The high success rate and less post-operative complication rate associated with embolotherapy procedures coupled with the rising incidences of liver cancer and hepatocellular cancer are the key factors fueling the demand for embolotherapy devices for cancer disease indication. For instance, liver cancer is the fifth most common cancer in men and the ninth most common in women.

"The embolic agents segment, by product, is to register a significant growth rate owing to new product approvals"

Based on product, the embolotherapy market is broadly segmented into embolic agents and support devices. The embolic agents segment is further subsegmented into embolic coils, embolic plug systems, liquid embolic agents, microspheres, and detachable balloons. Whereas, the support devices segment includes microcatheters and guidewires. The embolic agents segment is anticipated to register the highest growth over the forecast period owing to new product approvals and launches in the segment. For instance, in 2019, Terumo received the FDA Premarket Approval (PMA) for the 'WEB Aneurysm Embolization System.' Moreover, in 2018, Medtronic launched OptiSphere embolization spheres in the US as well as the Concerto 3D detachable coil system in Ireland.

"The US market, by region, commanded the largest market share in 2018"

On the basis of region, the embolotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The US held the major share of the global embolotherapy market in 2018. Factors such as the favorable reimbursement scenario in the US, growing target patient population (CVDs, neurovascular diseases, cancer, and uterine fibroids), increasing preference for minimally invasive procedures, new product launches and technological advancements in embolotherapy devices, and the presence of key players in the region are driving the growth of the embolotherapy market in the US.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 - 25%, Tier 2 - 30%, and Tier 3 - 45%
  • By Designation: C-level - 26%, Director-level - 30%, and Others - 44%
  • By Country: North America- 34%, Europe - 26%, APAC - 23%, and RoW - 17%

The major players in the market include: Boston Scientific Corporation (US), Merit Medical Systems (US), Terumo Corporation (Japan), Medtronic plc (Ireland), Johnson & Johnson (US), Stryker Corporation (US), BTG plc (UK), Penumbra, Inc. (US), Cook Medical (US), Abbott Laboratories (US), Acandis GmbH (Germany), BALT Extrusion (France), Sirtex Medical Limited (Australia), Kaneka Corporation (Japan), and Meril Life Sciences Pvt. Ltd. (India) among others.

Research Coverage:

This report studies the embolotherapy market based on product, disease indication, procedure, end user, and region. The report also studies factors such as drivers, restraints, opportunities, and challenges affecting market growth. It also provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to individual growth trends, and it also forecasts the revenue of the market segments with respect to four main countries.

Key Benefits of Buying the Report:

This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; and high-growth countries along with their respective drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 PRIMARY RESEARCH VALIDATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 EMBOLOTHERAPY: MARKET OVERVIEW
  • 4.2 EMBOLOTHERAPY MARKET, BY PRODUCT
  • 4.3 EMBOLOTHERAPY MARKET, BY PROCEDURE AND REGION
  • 4.4 EMBOLOTHERAPY MARKET, BY DISEASE INDICATION
  • 4.5 ASIA PACIFIC EMBOLOTHERAPY MARKET, BY END USER AND COUNTRY
  • 4.6 GEOGRAPHIC SNAPSHOT OF THE EMBOLOTHERAPY MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing target patient population
      • 5.2.1.2 Rising patient preference for minimally invasive procedures
      • 5.2.1.3 Funding & investments by government and private organizations
      • 5.2.1.4 Technological advancements in embolotherapy devices
      • 5.2.1.5 Favorable reimbursement scenario for minimally invasive surgeries
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lack of sufficient evidence & unfavorable regulatory scenario
      • 5.2.2.2 Strong market positioning of alternative therapies
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities offered by emerging markets
      • 5.2.3.2 Expanding applications of embolization devices
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Dearth of skilled surgeons
      • 5.2.4.2 High costs and resulting difficulties in accessing embolization in developing countries

6 EMBOLOTHERAPY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 EMBOLIC AGENTS
    • 6.2.1 MICROSPHERES
      • 6.2.1.1 Preference for alternative procedures limits the growth of this market segment
    • 6.2.2 EMBOLIC COILS
      • 6.2.2.1 Detachable coils
        • 6.2.2.1.1 Detachable coils can be retracted and redeployed a number of times until satisfactory placement is reached, which is a key advantage of this product segment
      • 6.2.2.2 Pushable coils
        • 6.2.2.2.1 Use of pushable coils increases the risk of non-target vascular blockages, thereby hampering their use in various applications
    • 6.2.3 LIQUID EMBOLIC AGENTS
      • 6.2.3.1 Significant adoption of embolic coils due to their procedural benefits over liquid embolic agents is expected to restrict market growth
    • 6.2.4 EMBOLIC PLUG SYSTEMS
      • 6.2.4.1 Procedural advantages delivered by vascular plugs such as a significantly shorter occlusion time and recanalization rate are the key factors leading to their increased adoption
    • 6.2.5 DETACHABLE BALLOONS
      • 6.2.5.1 Adverse events associated with the use of detachable balloons such as balloon rupture, failure, or shrinkage may limit the utilization of this embolic device
  • 6.3 SUPPORT DEVICES
    • 6.3.1 MICROCATHETERS
      • 6.3.1.1 Advancements and regulatory approvals in microcatheter technologies are expected to result in their wider adoption
    • 6.3.2 GUIDEWIRES
      • 6.3.2.1 Rising adoption of guidewires among medical professionals owing to their procedural benefits is expected to drive market growth

7 EMBOLOTHERAPY MARKET, BY DISEASE INDICATION

  • 7.1 INTRODUCTION
  • 7.2 CANCER
    • 7.2.1 LIVER CANCER
      • 7.2.1.1 Rising prevalence of liver cancer is projected to fuel segment growth
    • 7.2.2 KIDNEY CANCER
      • 7.2.2.1 The wide adoption of preoperative kidney tumor embolization in the treatment of kidney cancer is driving market growth
    • 7.2.3 OTHER CANCERS
      • 7.2.3.1 Increasing clinical research to check the effectiveness of embolization for cancer treatment to drive market growth
  • 7.3 PERIPHERAL VASCULAR DISEASE
    • 7.3.1 RISING ADOPTION OF VASCULAR PLUGS IS A KEY DRIVING FACTOR FOR THE MARKET
  • 7.4 NEUROLOGICAL DISEASES
    • 7.4.1 CEREBRAL ANEURYSM
      • 7.4.1.1 Limited availability of reimbursements across major markets may hinder market growth
    • 7.4.2 ARTERIOVENOUS MALFORMATION AND FISTULAS
      • 7.4.2.1 Side effects associated with AVM embolization procedures may restrict market growth to a certain extent
  • 7.5 UROLOGICAL & NEPHROLOGICAL DISORDERS
    • 7.5.1 EMBOLIC AGENTS ARE USED TO TREAT UTERINE FIBROIDS, AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, AND BENIGN PROSTATIC HYPERPLASIA
  • 7.6 GASTROINTESTINAL DISORDERS
    • 7.6.1 EMBOLIZATION IS A WIDELY ADOPTED PROCEDURE USED TO TREAT LGIB AND UGIB

8 EMBOLOTHERAPY MARKET, BY PROCEDURE

  • 8.1 INTRODUCTION
  • 8.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE)
    • 8.2.1 TRANSCATHETER ARTERIAL EMBOLIZATION DOMINATES THE EMBOLOTHERAPY MARKET DUE TO THE INCREASING INCIDENCE OF UTERINE FIBROIDS & VASCULAR LESIONS
  • 8.3 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION (TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
    • 8.3.1 BETTER CLINICAL OUTCOMES & INCREASED CANCER SURVIVAL RATE ARE SUPPORTING THE GROWTH OF THIS SEGMENT
  • 8.4 TRANSARTERIAL CHEMOEMBOLIZATION (TACE)
    • 8.4.1 TACE CAN BE USED TO TREAT TUMORS THAT ARE RELATIVELY LARGER IN SIZE, WHICH CANNOT BE EASILY TREATED BY TUMOR ABLATION

9 EMBOLOTHERAPY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS AND CLINICS
  • 9.3 AMBULATORY SURGERY CENTERS
  • 9.4 OTHER END USERS

10 EMBOLOTHERAPY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 US
      • 10.2.1.1 The US dominates the global embolotherapy market in 2018 due to the large R&D investments in the country
    • 10.2.2 CANADA
      • 10.2.2.1 High burden of cancer to support market growth
  • 10.3 EUROPE
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany is the fastest-growing market in Europe
    • 10.3.2 UK
      • 10.3.2.1 Increasing incidence of target health conditions coupled with the rising geriatric population to drive market growth
    • 10.3.3 FRANCE
      • 10.3.3.1 Government initiatives to raise awareness about embolotherapy will increase the adoption of embolization procedures in the country
    • 10.3.4 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 JAPAN
      • 10.4.1.1 Growing geriatric population and the increasing R&D investments in the country are the major factors driving market growth
    • 10.4.2 CHINA
      • 10.4.2.1 China to register the highest growth in the APAC embolotherapy market due to the growing target patient population
    • 10.4.3 INDIA
      • 10.4.3.1 Ongoing modernization and expansion of healthcare infrastructure and growing medical tourism to support market growth
    • 10.4.4 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 BRAZIL
      • 10.5.1.1 Increasing incidence of hepatocellular carcinoma and cerebral aneurysm to drive the adoption of embolization products
    • 10.5.2 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS
    • 11.2.1 MARKET SHARE ANALYSIS FOR MICROSPHERES (2018)
    • 11.2.2 MARKET SHARE ANALYSIS FOR EMBOLIZATION COILS (2018)
  • 11.3 COMPETITIVE SITUATION AND TRENDS
  • 11.4 COMPETITIVE LEADERSHIP MAPPING
  • 11.5 VENDOR INCLUSION CRITERIA
  • 11.6 VENDOR DIVE
    • 11.6.1 VISIONARY LEADERS
    • 11.6.2 INNOVATORS
    • 11.6.3 DYNAMIC DIFFERENTIATORS
    • 11.6.4 EMERGING PLAYERS

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 12.1 ABBOTT LABORATORIES
  • 12.2 ACANDIS GMBH
  • 12.3 BALT EXTRUSION
  • 12.4 BOSTON SCIENTIFIC CORPORATION
  • 12.5 BTG PLC
  • 12.6 COOK MEDICAL
  • 12.7 JOHNSON & JOHNSON
  • 12.8 KANEKA CORPORATION
  • 12.9 MEDTRONIC PLC
  • 12.10 MERIL LIFE SCIENCES PVT., LTD.
  • 12.11 MERIT MEDICAL SYSTEMS
  • 12.12 PENUMBRA, INC.
  • 12.13 SIRTEX MEDICAL LIMITED
  • 12.14 STRYKER CORPORATION
  • 12.15 TERUMO CORPORATION

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
Back to Top